Manhattan Scientifics Inc. (OTCMKTS:MHTX) Stock Surges Announcing Early Results from Cancer Company

Manhattan Scientifics Inc. (OTCMKTS:MHTX) was up 13% after announcing positive results from ImagionBiosystems Cancer Diagnostics human trial.

Market Stats

On Thursday, MHTX stock gained 13.33% to $0.0136 with more than 336K shares, compared to its average volume of 147K shares. The stock moved within a range of $0.0123 – 0.0160 after opening trading at $0.0130.

Manhattan Scientifics Announces Early Results from Cancer Company

Following the announcement, ImagionBiosystems shares jumped 46%. Manhattan Scientifics initially funded and currently owns over 50 million ImagionBiosystems shares. Imagion is currently focused on creating new super-sensitive and non-radioactive diagnostic imaging tech for the early detection of cancer.

Manhattan Scientifics, a tech incubator in the United States, creates and markets, and sells life-enhancing innovations. It researches and develops nanotechnology and nanomedicine technologies. Grand Enterprises, Inc. was the company’s previous name. Manhattan Scientifics, Inc. is headquartered in New York and was founded in 1992.

So far, Manhattan Scientifics, which focuses on tech transfer and marketing transformative technologies, has been instrumental in incubation and financing four IPOs that work closely with Science Teams at Sandia National Laboratory and Los Alamos National Laboratory in New Mexico. Therefore with these development, investors should keep an eye on MHTX in the coming weeks.

Traders Corner

MHTX stock is trading above the 20-Day and 50-Day Moving averages of $0.0125 and $0.0136 respectively. Moreover, the stock is trading above the 200-Day moving average of $0.0126.